Anti-Microbial Resistance



The impact of rising resistance has made the development of effective vaccines against otherwise lethal bacterial infections paramount. 

While efforts towards developing new and effective antibiotics will take a number of years, vaccines could provide the immunity that could help us in catching up with the arms race.

For the third year running, we’re dedicating an entire day to AMR sessions, planned together with Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development at Janssen and Dr Kathrin Jansen, VP, CSO Bacterial Vaccines at Pfizer to cover the role of vaccines, public awareness and industry in preventing a further AMR crisis.

Who Sponsors?



This is a prime opportunity for specialists in oncology from:

  • CROs and Pre-Clinical CROs 
  • Drug Discovery, Collaborative Data, Registries, Translational Science and Academia/Research Institutes 
  • Consultants (Reg/Mkt Access/Comm) 
  • Biopharma, Biotech, Biofilm 
  • Molecular Diagnostics, In-Vitro Diagnostics, Point-of-Care Diagnostics, Antimicrobial testing labs
  • Bioinformatics, bioanalytics, biodata tech, biosimulation
  • Stewardship 
  • CMOs, Equipment, consumables

Who Attends



  • Pharma 
  • Biotech
  • Government
  • Academia & Research Institutions 
  • Public Agencies & Associations 

Job Titles



  • CEO
  • Chief/VP of R&D
  • Head, SVP, VP, Director of: Infectious Diseases 
  • President, Global Development
  • VP, Clinical Development
  • Chief Medical Officer
  • VP of Microbiology
  • VP of Antibacterial, Antibiotic
  • Principal Investigators
  • Scientists 
  • Strategic Alliance
  • Alliance/Partnership Development
  • VP of Microbiology

Sign Up for Event Updates